[go: up one dir, main page]

IN2014DN09410A - - Google Patents

Info

Publication number
IN2014DN09410A
IN2014DN09410A IN9410DEN2014A IN2014DN09410A IN 2014DN09410 A IN2014DN09410 A IN 2014DN09410A IN 9410DEN2014 A IN9410DEN2014 A IN 9410DEN2014A IN 2014DN09410 A IN2014DN09410 A IN 2014DN09410A
Authority
IN
India
Prior art keywords
proteomic profile
psg
fibronectin
expression
gestational diabetes
Prior art date
Application number
Inventor
Srinivasa R Nagalla
Original Assignee
Diabetomics Llc
Srinivasa R Nagalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diabetomics Llc, Srinivasa R Nagalla filed Critical Diabetomics Llc
Publication of IN2014DN09410A publication Critical patent/IN2014DN09410A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and more specifically to biomarkers for gestational diabetes. In various embodiments the methods may provide non- invasive and minimally- invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin SNA or a fibronectin antibody complex and PSG -AAL or a PSG antibody complex. In some embodiments the proteomic profile may also include information on the expression of adiponectin sex hormone binding globulin (SHBG), C- reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof.
IN9410DEN2014 2012-04-13 2013-03-11 IN2014DN09410A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623690P 2012-04-13 2012-04-13
PCT/US2013/030152 WO2013154709A1 (en) 2012-04-13 2013-03-11 Maternal biomarkers for gestational diabetes

Publications (1)

Publication Number Publication Date
IN2014DN09410A true IN2014DN09410A (en) 2015-07-17

Family

ID=49325612

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9410DEN2014 IN2014DN09410A (en) 2012-04-13 2013-03-11

Country Status (6)

Country Link
US (3) US8852873B2 (en)
EP (1) EP2836845B1 (en)
CN (1) CN104380112B (en)
ES (1) ES2684976T3 (en)
IN (1) IN2014DN09410A (en)
WO (1) WO2013154709A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160025737A1 (en) * 2014-07-25 2016-01-28 Diabetomics, Llc Biomarkers for assessment of preeclampsia
CA2979647C (en) * 2015-03-20 2023-07-18 Iq Products B.V. Novel marker for gestational diabetes
CN106706928A (en) * 2017-01-19 2017-05-24 深圳大学 Early prediction marker for gestational diabetes mellitus and detection method thereof
CN107024590A (en) * 2017-03-13 2017-08-08 新疆医科大学 A kind of serum protein markers group for diagnosing 1 type and diabetes B
CN113495150A (en) * 2020-03-19 2021-10-12 首都医科大学附属北京世纪坛医院 Application of urine albumin and polypeptide fragment thereof in gestational diabetes
CN113514634A (en) * 2020-04-09 2021-10-19 武汉市朗典精医生物科技有限公司 Preparation of double-index immunochromatography kit for detecting Adipo/SHBG
CN113804879A (en) * 2020-06-15 2021-12-17 北京康美天鸿生物科技有限公司 Helicobacter pylori IgM and IgG antibody combined detection kit
EP4428535A1 (en) * 2023-03-09 2024-09-11 Servizo Galego de Saude Diagnosis, monitoring or prognosis of diabetes or prediabetes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855242A (en) 1986-04-14 1989-08-08 Joslin Diabetes Center, Inc. Method of detecting antibodies
DE3800048A1 (en) 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh METHOD FOR DETERMINING AN ANTIBODY IN HUMAN BODY LIQUIDS
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5175085A (en) 1990-02-20 1992-12-29 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus
ES2223039T3 (en) 1990-09-07 2005-02-16 The Regents Of The University Of California METHODS FOR DIAGNOSIS AND TREATMENT OF DIABETES.
US5512447A (en) 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
DE4129849A1 (en) 1991-02-14 1992-08-27 Boehringer Mannheim Gmbh MONOCLONAL ANTIBODIES AGAINST HUMANE PANCREAS ISLAND CELLS
JPH06508030A (en) 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド Cloning and expression of human pancreatic islet glutamate decarboxylase autoantigen
US5674692A (en) 1991-09-06 1997-10-07 Baekkeskov; Steinunn Methods for diabetes susceptibility assessment in asymptomatic patients
US5200318A (en) 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5691448A (en) 1992-12-03 1997-11-25 Baekkeskov; Steinunn Reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
IL108587A (en) 1993-02-09 1998-01-04 Univ Monash Methods and kit for the diagnosis of diabetes and prediabetic conditions
ATE221200T1 (en) 1993-04-16 2002-08-15 Univ California METHOD FOR DETERMINING SUSPENSION TO DIABETES IN ASYMPTOMATIC PATIENTS
US5547847A (en) 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes
US5561049A (en) 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5989551A (en) 1995-10-25 1999-11-23 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods for detection and treatment of insulin-dependent diabetes
US6391651B1 (en) 1995-08-11 2002-05-21 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Materials and methods for detection of insulin dependent diabetes
US5821334A (en) 1996-01-26 1998-10-13 Vanderbilt University Insulin-dependent diabetes mellitus-specific chimeric polypeptides
EP0929683A1 (en) 1996-03-06 1999-07-21 ZymoGenetics, Inc. DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE
US5670377A (en) * 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes
AUPO468597A0 (en) 1997-01-21 1997-02-13 Montech Medical Developments Pty Ltd Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
DE19839736A1 (en) 1998-09-01 2000-03-02 Roche Diagnostics Gmbh Human monoclonal antibodies against islet cell antigen IA-2
WO2002033408A1 (en) 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting an inflammatory indicator in a body fluid sample
JP4594588B2 (en) 2001-04-10 2010-12-08 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Therapeutic and diagnostic uses of antibody-specific profiles
US20050130245A1 (en) 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
WO2003102147A2 (en) 2002-05-29 2003-12-11 University Of Washington Mutants of gad65 and ian5 relating to diabetes
FR2847263B1 (en) 2002-11-18 2006-01-13 Commissariat Energie Atomique SPECIFIC POLYNUCLEOTIDE OF THE PANCREATIC CELL BETA OF THE ISLANDS OF LANGERHANS
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
WO2004111608A2 (en) 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
JP4717810B2 (en) 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド Biomarkers for distinguishing between type 1 diabetes and type 2 diabetes
TW200508609A (en) 2003-07-15 2005-03-01 Bioarray Solutions Ltd Detection of cell membrane-associated proteins using membrane fragments displayed on encoded microparticle arrays
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
SE0400683D0 (en) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
EP1778874B1 (en) * 2004-07-30 2011-11-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for cervical cancer
ITRM20050398A1 (en) 2005-07-26 2007-01-27 Gian Franco Bottazzo METHOD FOR DETECTION OF T CELLS IN NEODIAGNOSTICATED PATIENTS FOR TYPE 1 DIABETES.
CA2624900A1 (en) * 2005-10-04 2007-04-19 The Research Foundation Of State University Of New York Fibronectin polypeptides and methods of use
WO2007062789A1 (en) 2005-11-29 2007-06-07 F. Hoffmann-La Roche Ag Fibronectin as target/marker for insulin resistance
CN101416063A (en) 2006-02-06 2009-04-22 拉帕波特家族医学科学研究所 Methods and kit for diagnosing T1DM
US20070224638A1 (en) 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
PL2118309T3 (en) 2006-12-29 2015-07-31 Univ Colorado Regents Diagnostic and therapeutic target for autoimmune diseases and uses thereof
DK2121905T3 (en) 2007-02-21 2016-05-17 Univercell Biosolutions HUMAN pancreatic beta-CELL LINES FOR DIAGNOSIS OF DIABETES
EP2198304B1 (en) 2007-09-06 2016-01-13 University of Washington Molecules and methods for treatment and detection of diabetes
WO2009045403A2 (en) 2007-10-01 2009-04-09 The Board Of Trustees Of The Leland Stanford Junior University MENIN REGULATION OF β-ISLET CELL PROLIFERATION
US20100017143A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US9176120B2 (en) 2008-02-04 2015-11-03 Women & Infants' Hospital Of Rhode Island Serum-based, diagnostic, biological assay to predict pregnancy disorders
US8722343B2 (en) 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
KR101067815B1 (en) 2009-02-05 2011-09-27 서울대학교산학협력단 New Diagnostic Markers of Type 1 Diabetes
WO2011085057A2 (en) 2010-01-06 2011-07-14 The Regents Of The University Of Colorado, A Body Corporate Methods for detecting insulin autoantibody
US8748352B2 (en) 2011-08-16 2014-06-10 Battelle Memorial Institute Peptide and protein biomarkers for type 1 diabetes mellitus

Also Published As

Publication number Publication date
US9383370B2 (en) 2016-07-05
ES2684976T3 (en) 2018-10-05
EP2836845A1 (en) 2015-02-18
EP2836845B1 (en) 2018-05-09
US20130274123A1 (en) 2013-10-17
CN104380112B (en) 2017-05-24
US8852873B2 (en) 2014-10-07
US20140080157A1 (en) 2014-03-20
US8975034B2 (en) 2015-03-10
CN104380112A (en) 2015-02-25
WO2013154709A1 (en) 2013-10-17
EP2836845A4 (en) 2015-11-18
US20150037822A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
IN2014DN09410A (en)
Abdel-Khalik et al. Simultaneous determination of endogenous steroid hormones in human and animal plasma and serum by liquid or gas chromatography coupled to tandem mass spectrometry
Rodríguez-Suárez et al. Urine as a source for clinical proteome analysis: from discovery to clinical application
Picariello et al. The frontiers of mass spectrometry-based techniques in food allergenomics
WO2014144129A3 (en) Biomarkers and methods for predicting preterm birth
EP3182126A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
WO2009006323A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
MX390227B (en) IMPROVED DEVICE AND METHOD FOR PREGNANCY TESTING.
WO2014143977A3 (en) Biomarkers and methods for predicting preeclampsia
EP2772761A3 (en) Nucleic acid element for use in analysis, and analytical method, analytical reagent and analytical instrument using same
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
IL302061B2 (en) Model based prediction in a critically sampled filterbank
WO2015031676A3 (en) Integrity testing of hair samples
WO2013087887A3 (en) Biomarkers and parameters for preeclampsia
MX369610B (en) Methods, devices, and systems for sample analysis.
BR112012024206B8 (en) method of detecting cells that are difficult to remove hemoglobin, and automatic method of quantifying cells that are difficult to remove hemoglobin
MX2020010714A (en) METHODS TO QUANTIFY IL-33.
EP3736571A4 (en) Method, reagent, and chip, for measuring analyte concentration in biological sample
Żurawicz et al. Analysis of amino acids in autism spectrum disorders
WO2013076579A3 (en) Method for assessing risk of bone fracture
WO2012054824A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2015086727A3 (en) New prognostic method for patients suffering of a cancer
WO2013006278A3 (en) Identity elucidation of unknown metabolites
WO2012100190A3 (en) Identifying location biomarkers
WO2014151079A3 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer